Piv5 As An Oncolytic Agent


The present invention includes the Paramyxovirus Parainfluenza Virus 5 (PIV5) as an oncolytic agent for treating various cancers, including, but not limited to breast cancer, lung cancer and melanoma. PIV5 oncolytic agents include both wild type PIV5 and various recombinant PIV5 constructs. Recombinant PIV5 constructs may include PIV5 lacking the conserved C-terminus of the V protein (PIV5VΔC), PIV5 with mutations in the N-terminus of the V/P protein (PIV5CPI−), and PIV5 expressing MDA-7/IL-24 (rPIV5-MDA7), rPIV5-V/P-CPI−, rPIV5-CPI+, rPIV5-Rev, rPIV5-RL, rPIV5-P-S157A, rPIV5-P-S308A, rPIV5-L-A1981D, rPIV5-F-5443P, rPIV5-MDA7, rPIV5ΔSH-CPI−, or rPIV5ΔSH-Rev. Also included are methods of making and using such oncolytic agents and compositions including such oncolytic agents.

Download PDF
Document Preview
Document History
  • Publication: Jun 25, 2019
  • Application: Jun 30, 2017
    US US 201715638946 A
  • Priority: Jun 30, 2017
    US US 201715638946 A
  • Priority: Jul 23, 2014
    US US 201414374070 A
  • Priority: Jan 24, 2013
    US US 2013/0022898 W
  • Priority: Aug 16, 2012
    US US 201261683810 P
  • Priority: Jan 24, 2012
    US US 201261590070 P
  • Priority: Jan 24, 2012
    US US 201261590056 P

Download Citation

Sign in to the Lens